Related Experiment Video
Updated: Feb 24, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Founder mutation for Huntington disease in Caucasus Jews
1The Raphael Recanati Genetic Institute, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Insights
Huntington disease (HD) is more prevalent in Caucasus Jews (CJ) due to a recent founder mutation. This suggests a higher incidence in this group, warranting increased clinical suspicion for HD in CJ individuals.
Area of Science:
- Genetics
- Neurology
- Population Studies
Background:
- Huntington disease (HD) is an autosomal dominant neurodegenerative disorder.
- Diagnosis and onset age are linked to CAG repeat expansion in the HTT gene.
- HD prevalence is established in Europeans but not well-studied in Israeli populations.
Purpose of the Study:
- To investigate the prevalence and genetic origins of Huntington disease (HD) in the Israeli population.
- To determine if a founder mutation exists within specific Jewish subgroups.
Main Methods:
- Haplotype analysis of ten HD probands diagnosed between 2006-2011.
- Focus on nine Caucasus Jewish (CJ) and one Ashkenazi Jewish proband.
- Calculation of mutation coalescence age.
Main Results:
- Eight of nine CJ probands shared a common haplotype (A1 haplogroup), suggesting a founder effect.
- The mutation's coalescence age was estimated between 80-150 years.
- CJ constitute 90% of local HD patients and 27% of all Israeli HD cases, despite being 1.4% of the population.
Conclusions:
- HD prevalence is significantly higher among Caucasus Jews (CJ) in Israel compared to the general population.
- Findings support a recent founder mutation for HD within the CJ community.
- Increased clinical suspicion for HD is recommended in CJ individuals presenting with subtle symptoms.
Abstract:
Huntington disease (HD), an autosomal dominant disorder involving HTT, is characterized by chorea, psychiatric illness and cognitive decline. Diagnosis and age of onset depend on the degree of expansion of the trinucleotide CAG repeat within the gene. The prevalence of HD is known for Europeans but has not been studied in the Israeli population. Between 2006 and 2011 we diagnosed in our adult genetics clinic ten HD probands, nine of whom were Caucasus Jews (CJ) (Azerbaijani), and one Ashkenazi Jewish. We performed haplotype analysis to look for evidence of a founder mutation, and found that of the nine CJ, eight shared the same haplotype that was compatible with the A1 haplogroup. We calculated the coalescence age of the mutation to be between 80 and 150 years. Ninety percent of our HD patients are CJ, as are 27% of the HD patients in Israel, although the CJ comprise only 1.4% of the Israeli population. Our findings suggest a higher prevalence of HD among CJ compared to the general Israeli population and are consistent with a recent founder mutation. We recommend a higher degree of suspicion for HD in CJ with subtle clinical findings.
Related Concept Videos
Point and Frameshift Mutations
Spontaneous and Induced Mutations
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...

